Investigational drugs for anxiety in patients with schizophrenia

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 507-517

  Garay, Ricardo P ^a,b   Samalin, Ludovic ^c   Hameg, Ahcène ^b   Llorca, Pierre Michel ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Craven ^*  (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Anxiety; Clinical trials; Pregabalin; Quetiapine; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ARMODAFINIL; ASENAPINE; BENZODIAZEPINE DERIVATIVE; BITOPERTIN; CANNABIDIOL; FAMOTIDINE; LURASIDONE; OXYTOCIN; PREGABALIN; PREGNENOLONE; QUETIAPINE; THEANINE; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; NEW DRUG;

ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COMORBIDITY; DATA BASE; DISEASE MODEL; HUMAN; MEDICAL RESEARCH; MENTAL PATIENT; OUTCOME ASSESSMENT; REVIEW; SCHIZOPHRENIA; SCIENTIFIC LITERATURE; ANIMAL; ANXIETY; DRUG DESIGN; ETIOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; SCHIZOPHRENIA;

EID: 84924680704     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.987339     Document Type: Review

References (74)

1. Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013;150:3-10
2. Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317-33
3. Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res 2014;54:85-93
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
5. Llorca P-M, Lancon C, Blanc O, et al. A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). Eur Arch Psychiatry Clin Neurosci 2014;264:171-8
6. Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res 2013;210:1-7
7. Pallanti S, Cantisani A, Grassi G. Anxiety as a Core Aspect of Schizophrenia. Curr Psychiatry Rep 2013;15:1-5
8. Achim AM, Maziade M, Raymond E, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2009;37(4):811-21
9. Bayle FJ, Blanc O, De Chazeron I, et al. Prise en charge medicamenteuse de l'anxiete chez le patient souffrant de schizophrenie. L'Encephale 2011;37(Suppl 1):S83-S9
10. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56
11. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-78
12. Stahl SM, Morrissette DA, Citrome L, et al. "Meta-guidelines" for the management of patients with schizophrenia. CNS Spectr 2013;18:150-62
13. NICE (National Institute for Health and Care Excellence). Psychosis and schizophrenia in adults: treatment and management. NICE guidelines [CG178] 2014. Avilable from http://www.nice.org. uk/guidance/CG178
14. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
15. Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2012;11:CD006391
16. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010;71:103-8
17. Sim F, Sweetman I, Kapur S, et al. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol 2014. doi: 10.1177/0269881114541013
18. National Institutes of Health, USA. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov
19. European Medicines Agency. EU Clinical Trials Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search;jsessionid=sa0a1Jq2IuPPzCaQoIpa EOkYugzkgm-2UA9T- Bmp3ks9p4LXbe5D!-895578838
20. World Health Organization. International Clinical Registry Platform. Available from: http://apps.who.int/trialsearch/
21. Available from: http://www.ema.europa. eu
22. Food and Drug Administration, US. Available from: http://www.fda.gov
23. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extendedrelease formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin 2013;29:813-25
24. Lecrubier Y, Azorin M, Bottai T, et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44:41-6
25. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag 2011;7:239-50
26. Tarazi FI, Riva MA. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin Drug Discov 2013;8:1297-307
27. Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2014;19:330-9
28. Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther 2012;34:1023-40
29. Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf 2014;13:803-30
30. Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 2013;9:883-92
31. Both C, Kojda G, Lange-Asschenfeldt C. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Expert Rev Neurother 2014;14:29-38
32. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 2012;46:424-9
33. Feifel D. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 2012;37:304-5
34. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012;35:649-59
35. Jewell R. Famotidine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Elsevier; New York: 2007. p. 1-5
36. Ekelund H, Meskanen K, Laitinen J, et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol 2013;33:472-8
37. Leweke FM, Koethe D, Gerth CW, et al. Cannabidiol as an antipsychotic agent. Eur Psychiatry 2007;22(Suppl 1):S21
38. Crippa JAS, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011;25:121-30
39. Wittkampf LC, Arends J, Timmerman L, et al. A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol 2012;2:115-25
40. Kane JM, Yang R, Youakim JM. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2012;135:116-22
41. Umbricht D, Alberati D, Martin-Facklam M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71:637-46
42. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets 2014;18:1049-63
43. Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebocontrolled, 2-center study. J Clin Psychiatry 2011;72:34-42
44. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 2010;71:1351-62
45. Marx CE, Bradford DW, Hamer RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011;191:78-90
46. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
47. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 2010;4:189-200
48. Amiel JM, Mathew SJ. Glutamate and anxiety disorders. Curr Psychiatry Rep 2007;9:278-83
49. Schonfeldt-Lecuona C, Wolf RC, Osterfeld ND, et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2009;42:124-5
50. Englisch S, Eer A, Enning F, et al. Augmentation With Pregabalin in Schizophrenia. J Clin Psychopharmacol 2010;30:437-40
51. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebocontrolled trials. Curr Med Res Opin 2004;20:1357-63
52. Boyer P, Lecrubier Y, Stalla-Bourdillon A, et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999;39:25-32
53. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a doubleblind, comparative study. J Affect Disord 1998;48:47-56
54. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia Patients. Neuropsychopharmacology 2011;36:1219-26
55. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812
56. Sabihi S, Durosko NE, Dong SM, et al. Oxytocin in the prelimbic medial prefrontal cortex reduces anxiety-like behavior in female and male rats. Psychoneuroendocrinology 2014;45:31-42
57. Martinez MC. Famotidine in the management of schizophrenia. Ann Pharmacother 1999;33:742-7
58. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry 2014;75(Suppl 1):21-6
59. Available from: http://www.roche.com/media/media-releases/med-cor-2014-01-21.htm
60. Miodownik C, Maayan R, Ratner Y, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to l-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol 2011;34:155-60
61. Stern RG, Petti TA, Bopp K, et al. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol 2009;29:206-9
62. Burda K, Czubak A, Kus K, et al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011;63:898-907
63. Egashira N, Okuno R, Matsushita M, et al. Aripiprazole inhibits marbleburying behavior via 5-hydroxytryptamine (5-HT)1A receptorindependent mechanisms. Eur J Pharmacol 2008;592:103-8
64. Worthington JJ, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11
65. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005;86:99-104
66. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007;27:207-10
67. Katzman MA. Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. J Affect Disord 2011;128:S11-20
68. Sayyah M, Sayyah M, Boostani H, et al. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 2012;29:850-4
69. Zajdel P, Partyka A, Marciniec K BA, et al. Quinoline-and isoquinolinesulfonamide analogs of aripiprazole: novel antipsychotic agents? Future Med Chem 2014;6:57-75
70. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27:879-911
71. Allilaire JF. Angoisse psychotique et angoisse nevrotique. Difference qualitative ou difference quantitative? L'Encephale 1983;9(Suppl 2):211B-6B
72. Cutler JL, Siris SG. ''Panic-like'' symptomatology in schizophrenic and schizoaffective patients with postpsychotic depression: observations and implications. Compr Psychiatry 1991;32:465-73
73. HAS. Haute Autorite de Sante. Tercian. Commission de la Transparence 2012; Avis CT11921
74. Karam CS, Ballon JS, Bivens NM, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010;31:381-90